Novartis completed the acquisition of Kate Therapeutics for $1.1bn.

Novartis, a pharmaceutical company, completed the acquisition of Kate Therapeutics, a preclinical stage biotechnology company, for $1.1bn. “We are delighted to bring Kate Therapeutics’ platform technologies and programs together with Novartis scientific expertise and leadership in gene therapy and neuroscience innovation. We have been highly impressed with the rigor and potential of Kate’s science, and we are confident this acquisition will further enhance our ability to bring forward new therapeutic options for patients living with neuromuscular diseases,” Fiona Marshall, Novartis President of Biomedical Research.